| 王彦志,刘亚光,刘鹏霞.程序性死亡分子1/程序性死亡配体1抗体治疗人类癌症的研究进展[J].安徽医药,2017,21(3):395-398. |
| 程序性死亡分子1/程序性死亡配体1抗体治疗人类癌症的研究进展 |
| Research progress in PD-1/PD-L1 antibodies treating human cancers |
| 投稿时间：2016-06-08 |
| DOI： |
| 中文关键词: 肿瘤治疗方案 抗体,单克隆 抗原,CD274 肿瘤逃逸 |
| 英文关键词: Antineoplastic protocols Antibodies,monoclonal Antigens,CD274 Tumor escape |
| 基金项目:国家自然科学基金项目(31101698)；内蒙古杰出青年自然科学基金项目(2011JQ03) |
|
| 摘要点击次数: 2935 |
| 全文下载次数: 902 |
| 中文摘要: |
| 目前,人们已经开始利用单克隆抗体阻碍程序性死亡分子1/程序性死亡配体1途径(PD途径)来治疗癌症,尤其是晚期实体瘤。笔者简要回顾PD抗体治疗的历史和发展进程,从最初的实验工作到最新的临床结果,并举例阐述PD抗体应用的主要癌症类型及其代表性实验。重点讨论PD抗体治疗所涉及的三大重要原理,并指出该疗法与其他免疫治疗相比有何独到之处。这些基本的原理将为未来的免疫疗法设立标准,指导进一步开发更有效、毒性更低的抗肿瘤疗法。 |
| 英文摘要: |
| Major progress has been made toward our understanding of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred to as the PD pathway).Monoclonal antibodies (mAbs) are already being used to block the PD pathway to treat human cancers,especially advanced solid tumors.In this review,we will briefly review the history and development of anti-PD therapy,from the original bench work to the most up-to-date clinical results.Examples will be given to illustrate main types of cancer that PD-1/PD-L1 mAbs are being used to treat and its representative experiments.Then we will focus the discussion on three basic principles that define this unique therapeutic approach and highlight how anti-PD therapy is distinct from other immunotherapeutic approaches.We believe that these fundamental principles set the standard for future immunotherapies and will guide our efforts to develop more efficacious and less toxic immune therapeutics to treat human cancers. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
